Pediatric brain tumors remain one of the most aggressive and life-threatening diseases in children, accounting for a significant portion of cancer-related morbidity and mortality globally. Despite advances in molecular profiling and treatment techniques, therapeutic results for many juvenile brain tumors, such as medulloblastoma and glioblastoma, are still poor. Understanding the genetic and epigenetic pathways behind these cancers is crucial for creating targeted therapies. The SMYD gene family (SET and MYND domain-containing) encodes lysine methyltransferases that control chromatin remodeling, histone modification, and gene transcription. These genes, particularly SMYD2 and SMYD3, have been linked to a variety of adult cancers, where they increase cell proliferation, metastasis, and resistance to treatment by methylating histone and non-histone substrates. However, their exact involvement in pediatric brain tumors is little understood.

In this study, I conducted a thorough bioinformatics analysis of publicly accessible gene expression and clinical datasets to evaluate the expression patterns, pathway involvement, and prognostic value of SMYD family members in pediatric brain cancers. Differential expression analysis indicated continuous overexpression of SMYD3 and, to a lesser extent, SMYD2 in aggressive tumor subtypes, such as Group 3 medulloblastomas and high-grade gliomas. Functional enrichment and network analysis revealed that dysregulated SMYD genes are linked to key cancer pathways such as cell cycle progression, DNA repair, and chromatin modification. Furthermore, Kaplan-Meier survival analysis revealed that increased SMYD3 expression is associated with considerably lower overall survival, indicating its potential as a prognostic biomarker.

These findings highlight SMYD3 as a possible biological target for therapeutic intervention and support additional functional research to better understand its mechanistic role in juvenile neuro-oncology. This study adds to the emerging field of epigenetic cancer research by integrating transcriptome and survival data, emphasizing the necessity of exploring chromatin regulators in juvenile cancers. Finally, knowing the role of SMYD dysregulation in pediatric brain tumor biology may lead to the development of novel, focused therapy options that enhance patient outcomes.